SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Amgen Inc. (AMGN)
AMGN 317.74+0.1%Dec 12 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: tom pope5/17/2007 11:37:08 AM
  Read Replies (1) of 1906
 
ML

CERA PDUFA on May 20th provides AMGN derivative trading
opportunities.
Using our proprietary model, we predict stock reaction to a full FDA approval to be
($4) with a 40% chance, +$5 with not approvable decision (10% chance), +$3 with
major delay in approval (20% chance), and +$2 with minor delay (30% chance).

We expect Vol to increase thru October from multiple
catalysts.
3 major catalysts will increase the uncertainty surrounding the security of Amgen’s
$6.6 billion EPO franchise:
1. CMS policy revision, expected this summer
2. A Fall FDA EPO advisory panel for label deliberations
3. Commencement of intellectual property lawsuit with Roche in September

Option strategy: Use June vol to buy Oct. vol
We believe June options are fairly priced with June "near-the-money" straddles
pricing in a ~$3.50 move in either direction. Our scenario analysis leads to a
similar conclusion with a 60% probability that Roche's Mircera is hindered in some
way and a 40% probability that Roche is granted a full FDA approval. We further
expect vols to maintain these levels in the near-term and increase between now
October expiry based upon 3 crucial catalysts expected to transpire over the next
5-6 months. We recommend investors looking to add volatility exposure by
selling June vol and using the proceeds to purchase October vols.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext